With seventh person seemingly cured of HIV, signs of hope for a broader cure
A seventh person, dubbed "The Next Berlin Patient," is cured of HIV after a bone marrow transplant from a donor with a rare genetic mutation. This breakthrough offers hope for a broader cure approach.
Read original article
A seventh person, known as "The Next Berlin Patient," has been declared cured of HIV, providing hope for a broader cure approach for the 39 million people living with the virus globally. The patient underwent a bone marrow transplant with cells from a donor who was heterozygous for a rare genetic mutation that provides natural resistance to HIV. This treatment not only cured the patient's cancer but also seems to have eliminated the HIV virus from his body. The case will be presented at the 25th International AIDS conference in Munich. This breakthrough suggests that even with a functional receptor for the virus present, it may be possible to cure HIV by destroying the viral reservoir. The findings highlight the potential for gene therapies and long-term remission strategies in treating HIV. The patient has been in treatment-free HIV remission for almost six years, with no detectable signs of the virus in his blood or tissues.
Related
A new way to prevent HIV delivers dramatic results in trial
A trial of lenacapavir for HIV prevention showed 100% effectiveness, prompting a shift from daily pills to injections. Experts praise its potential for populations with adherence challenges, while efforts focus on accessibility and cost considerations.
Scientists create a cell that precludes malignant growth
Scientists at the University of Helsinki developed a cell preventing malignant growth, enhancing therapies for diseases like diabetes. Engineered cells show promise in regulating glucose levels and evading immune rejection, advancing safer cell therapies.
HIV breakthrough: Trial shows drug provides 100% protection
A trial in South Africa and Uganda revealed lenacapavir, a new PrEP drug given twice yearly, provided 100% protection against HIV in young women, outperforming daily options. The promising results may offer a more manageable prevention approach.
New HIV Prevention Drug Shows 100% Efficacy in Clinical Trial
A new HIV prevention drug, lenacapavir, has shown 100% efficacy in a trial in South Africa and Uganda for young women. It outperformed daily pills like Truvada and Descovy, offering hope for improved prevention methods.
Immunotherapy Is Changing Cancer Treatment Forever
Immunotherapy, especially in glioblastoma cases, has shown significant progress. Mass General researchers use genetically modified white blood cells to target tumors, leading to rapid regression. This innovative approach offers hope for challenging cancer cases.
4 commentsSeems very wrong.
Related
A new way to prevent HIV delivers dramatic results in trial
A trial of lenacapavir for HIV prevention showed 100% effectiveness, prompting a shift from daily pills to injections. Experts praise its potential for populations with adherence challenges, while efforts focus on accessibility and cost considerations.
Scientists create a cell that precludes malignant growth
Scientists at the University of Helsinki developed a cell preventing malignant growth, enhancing therapies for diseases like diabetes. Engineered cells show promise in regulating glucose levels and evading immune rejection, advancing safer cell therapies.
HIV breakthrough: Trial shows drug provides 100% protection
A trial in South Africa and Uganda revealed lenacapavir, a new PrEP drug given twice yearly, provided 100% protection against HIV in young women, outperforming daily options. The promising results may offer a more manageable prevention approach.
New HIV Prevention Drug Shows 100% Efficacy in Clinical Trial
A new HIV prevention drug, lenacapavir, has shown 100% efficacy in a trial in South Africa and Uganda for young women. It outperformed daily pills like Truvada and Descovy, offering hope for improved prevention methods.
Immunotherapy Is Changing Cancer Treatment Forever
Immunotherapy, especially in glioblastoma cases, has shown significant progress. Mass General researchers use genetically modified white blood cells to target tumors, leading to rapid regression. This innovative approach offers hope for challenging cancer cases.